Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D plus T) in patients (pts) with resected stage III BRAF-mutant melanoma

被引：3
|
作者：
Schadendorf, Dirk
Hauschild, Axel
Santinami, Mario
Atkinson, Victoria
Mandala, Mario
Chiarion-Sileni, Vanna
Larkin, James M. G.
Nyakas, Marta
Dutriaux, Caroline
Haydon, Andrew
Mortier, Laurent
Robert, Caroline
Schachter, Jacob
Ji, Ran
Aimone, Paola
Manson, Stephanie
Kefford, Richard
Dummer, Reinhard
Kirkwood, John M.
Long, Georgina V.
机构：
[1] Univ Hosp Essen, Essen, Germany
[2] Univ Hosp Schleswig Holstein, Kiel, Germany
[3] Fdn Ist Nazl Tumori, Milan, Italy
[4] Univ Queensland, Princess Alexandra Hosp, Gallipoli Med Res Fdn, Brisbane, Qld 4072, Australia
[5] Papa Giovanni XXIII Canc Ctr Hosp, Bergamo, Italy
[6] Veneto Oncol Inst, Melanoma Oncol Unit, Padua, Italy
[7] Royal Marsden NHS Fdn Trust, London, England
[8] Oslo Univ Hosp, Norwegian Radium Hosp, Oslo, Norway
[9] Ctr Hosp Univ Bordeaux, Hop St Andre, Bordeaux, France
[10] Alfred Hosp, Melbourne, Australia
[11] Univ Lille, INSERM, U 1189, Lille, France
[12] Inst Gustave Roussy, Paris, France
[13] Sheba Med Ctr, Ella Inst Melanoma, Tel Hashomer, Israel
[14] Novartis Pharmaceut, E Hanover, NJ USA
[15] Novartis AG, Basel, Switzerland
[16] Macquarie Univ, Melanoma Inst Australia, Westmead Hosp, Sydney, NSW, Australia
[17] Univ Sydney, Sydney, NSW, Australia
[18] Univ Hosp Zurich, Skin Canc Ctr, Zurich, Switzerland
[19] Univ Pittsburgh, Melanoma Program, Hillman UPMC Canc Ctr, Pittsburgh, PA USA
[20] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, Sydney, NSW, Australia
[21] Univ Sydney, Melanoma Inst Australia, Mater Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9590
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)
    Gogas, Helen
    Dummer, Reinhard
    Ascierto, Paolo A.
    Arance, Ana
    Mandala, Mario
    Liszkay, Gabriella
    Garbe, Claus
    Schadendorf, Dirk
    Krajsova, Ivana
    Gutzmer, Ralf
    Sileni, Vanna Chiarion
    Dutriaux, Caroline
    Yamazaki, Naoya
    Loquai, Carmen
    Queirolo, Paola
    de Willem, Groot Jan
    Sellier, Abir Tadmouri
    Suissa, Jeanne
    Murris, Juliette
    Gollerkeri, Ashwin
    Robert, Caroline
    Flaherty, Keith T.
    EUROPEAN JOURNAL OF CANCER, 2021, 152 : 116 - 128
  • [42] Health-related quality of life (HRQOL) in patients with ALK plus non-small cell lung cancer (NSCLC) in the phase III CROWN study
    Liu, G.
    Iadeluca, L.
    Reisman, A.
    Blackhall, F.
    Mazieres, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1056 - S1056
  • [43] Safety and effectiveness analysis of V600 BRAF-mutated metastatic melanoma (MM) patients (pts) from the dabrafenib (D) plus trametinib (T) named patient programme (NPP) - DESCRIBE II study
    Atkinson, V.
    Thienen, J. V.
    McArthur, G.
    Hospers, G.
    Long, G.
    Carnevale-Schianca, F.
    Tulyte, S.
    Stein, D.
    Bassel, M.
    Freivogel, K.
    Dalland, L.
    Lau, M.
    Legenne, P.
    Ferrucci, P. F.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S677 - S678
  • [44] HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis
    Oriol, Albert
    Richardson, Paul G.
    Mateos, Maria-Victoria
    Larocca, Alessandra
    Creixenti, Joan Blade
    Cavo, Michele
    Rodriguez-Otero, Paula
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Strang, Peter
    Sandberg, Anna
    Jaques, Christian
    Thuresson, Marcus
    Orre, Marie
    Leleu, Xavier
    BLOOD, 2020, 136
  • [45] Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
    Nathan, P.
    Dummer, R.
    Long, G. V.
    Ascierto, P. A.
    Tawbi, H. A.
    Robert, C.
    Rutkowski, P.
    Leonov, O.
    Dutriaux, C.
    Mandala', M.
    Lorigan, P.
    Ferrucci, P. F.
    Flaherty, K. T.
    Brase, J. C.
    Green, S.
    Haas, T.
    Masood, A.
    Gasal, E.
    Ribas, A.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S1172 - S1172
  • [46] Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC).
    Van Cutsem, Eric
    Singh, Prianka
    Cleary, James M.
    Kelly, Ronan Joseph
    Moehler, Markus H.
    Kuzdzal, Jaroslaw
    Mendez, Guillermo
    Motoyama, Satoru
    Elimova, Elena
    Grootscholten, Cecile
    Sun Xiaowu
    Taylor, Fiona
    Lawrance, Rachael
    Padilla, Brad
    Moreno-Koehler, Alejandro
    Zhang, Jenny
    Blum, Steven, I
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [47] Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HRD/HER2-early breast cancer (EBC)
    Fasching, P. A.
    Slamon, D.
    Nowecki, Z.
    Kukielka-Budny, B. D.
    Stroyakovskiy, D.
    Yardley, D.
    Huang, C.
    Chan, A.
    Chia, S.
    Martin, M.
    Rugo, H. S.
    Loi, S.
    Hurvitz, S. A.
    Untch, M.
    Afenjar, K.
    Fresco, R.
    Danyliv, A.
    Ferrusi, I.
    Li, Z.
    Hortobagyi, G. N.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 951 - 953
  • [48] Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial.
    Ascierto, Paolo Antonio
    Robert, Caroline
    Nathan, Paul D.
    Dummer, Reinhard
    Tawbi, Hussein Abdul-Hassan
    Flaherty, Keith T.
    Ribas, Antoni
    Schadendorf, Dirk
    Green, Steven
    Sandalic, Lali
    Lau, Mike R.
    Romero, Tonatiuh
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data.
    Weber, Jeffrey S.
    Gogas, Helen
    Sun, Xiaowu
    Yip, Christine
    Taylor, Fiona
    Braverman, Julia
    Lobo, Maurice
    Thakkar, Pratik K.
    Moshyk, Andriy
    Larkin, James
    Ascierto, Paolo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC)
    Planchard, D.
    Smit, E. F.
    Groen, H. J. M.
    Mazieres, J.
    Besse, B.
    Helland, A.
    Giannone, V.
    D'Amelio, A.
    Zhang, P.
    Mookerjee, B.
    Johnson, B.
    ANNALS OF ONCOLOGY, 2017, 28
12345